Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26295517 | 0.93 | POLB (0.48) | HRH2HRH1POLBRXFP1CHRM1 | |
| SCHEMBL4546644 | 0.85 | CHRM1 (0.47) | CHRM1HRH3KCNH2CYP2D6 | |
| SCHEMBL26295530 | 0.84 | FAAH (0.43) | MAOBHRH2HRH1POLBRXFP1 | |
| SCHEMBL26295527 | 0.84 | FAAH (0.46) | MAOBHRH2HRH1HRH3KCNH2 | |
| SCHEMBL1098571 | 0.82 | HRH2 (0.46) | HRH2HRH1POLBRXFP1HRH3 | |
| SCHEMBL1098569 | 0.82 | HRH2 (0.46) | HRH2HRH1POLBRXFP1HRH3 | |
| SCHEMBL20621097 | 0.82 | HRH2 (0.55) | HRH2HRH1POLBRXFP1TP53 | |
| SCHEMBL23349399 | 0.81 | MAOB (0.56) | MAOBHRH3TP53SMN1; SMN2DAO | |
| SCHEMBL6658550 | 0.81 | MAOB (0.56) | MAOBHRH3TP53SMN1; SMN2DAO | |
| SCHEMBL23842013 | 0.81 | HRH2 (0.45) | HRH2HRH1POLBRXFP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | ENDOTARGET INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | ENDOTARGET INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023177451-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | EnhancedBio Inc. (KR) | 2023-09-21 | — | — | WO | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | CDK6, CDK4, CDK1 | MAOB 2686/4885HRH2 4082/4885HRH1 2607/4885 |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | MAOB 1668/4885HRH2 3698/4885HRH1 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.